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Introduction
Osteoarthritis (OA) is the most common joint disorder in 
western countries, aﬀ  ecting over 70% of adults aged 55 to 
70 years [1,2]. It is characterized by progressive loss of 
articular cartilage, subchondral bone sclerosis, osteo-
phyte formation, and synovial inﬂ  ammation,  causing 
substantial physical disability, impaired quality of life, 
and signiﬁ  cant health care utilization. As OA incidence 
increases with age, OA will become a major health issue 
and socio-economic problem in the coming decades [3]. 
Historically, OA was seen as a degenerative disease 
caused solely by the ‘wear and tear’ process of ageing 
cartilage. Now it is recognized as a more dynamic, 
complex disease involving numerous factors aﬀ  ecting the 
whole joint [4]. Various risk factors for development of 
OA have been identiﬁ  ed - age, sex, and genetic and bio-
mechanical factors - contributing to degeneration of 
articular cartilage and changes in bone and synovium.
Traditionally, non-steroidal anti-inﬂ  ammatory  drugs 
(NSAIDs) have been used to treat pain and inﬂ  ammation 
in OA [5]. Th  e  anti-inﬂ  ammatory eﬀ  ects of NSAIDs are 
mainly due to their ability to inhibit cyclooxygenase 
(COX), impairing production of prostaglandins, which 
are important mediators of the inﬂ  ammatory response 
and pain. COX enzymes metabolize arachidonic acid, 
form  ing prostaglandin H2, which is subsequently metabo-
lized by prostaglandin E synthase into prostaglandin E2
(PGE2) [6]. Two isoforms of the COX enzyme exist: con-
stitutively expressed homeostatic COX-1 found in most 
tissues, and COX-2, which is not expressed in normal 
healthy tissues and cells but is induced by various pro-
inﬂ   ammatory, catabolic, and stress mediators, such as 
cytokines, growth factors, and increased loading [7]. 
Beneﬁ  cial eﬀ  ects of NSAIDs are thought to be mediated 
by COX-2 inhibition, whereas unwanted gastrointestinal 
eﬀ  ects are caused by inhibitory eﬀ  ects on COX-1 [8]. 
Th  is led to the development of selective COX-2 inhibi-
tors. Celecoxib (SC-58635; 4-[5-(4-methylphenyl)-3-
(triﬂ  uoromethyl)-1H-pyrazol-1-yl]benzenesulfon-amide) 
was the ﬁ  rst US Food and Drug Administration-approved 
selective COX-2 inhibitor and is now widely used in OA 
treatment [9].
Besides its anti-inﬂ   ammatory properties, evidence is 
accumulating that celecoxib has additional disease 
modify ing  eﬀ  ects. Celecoxib has been shown to aﬀ  ect all 
structures involved in OA pathogenesis: cartilage, bone, 
and synovium [10-12]. As well as COX-2 inhibition, 
evidence indicates that celecoxib also modulates COX-2-
independent signal transduction pathways [13]. Th  ese 
ﬁ  ndings raise the question of whether celecoxib is more 
than just an anti-inﬂ  ammatory and analgesic drug - does 
celecoxib also slow down OA disease progression and 
can it be viewed as a disease-modifying osteoarthritic 
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cartilage, bone, and synoviocytes in OA treatment are 
discussed.
It is important to note that some of the eﬀ  ects 
described may be related to the coxib class of drugs as a 
whole, some may be speciﬁ  c to celecoxib, and some may 
result from a general COX-inhibiting eﬀ  ect. Th  is  review 
does not intend to distinguish between these but focuses 
on the properties of celecoxib speciﬁ   cally. Only when 
celecoxib has been compared to other treatments have 
such comparisons been taken into account. Moreover, 
this review does not discuss the issue of side eﬀ  ects and 
clinical eﬃ   cacy of celecoxib, but focuses on its potential 
tissue structure-modifying, mostly chondroprotective, 
eﬀ  ects.
Methods
Two electronic databases were searched for relevant 
publications: PubMed (1990 to March 2010) and 
EMBASE (1990 to March 2010). Key words used were: 
celecoxib/Celebrex/SC-58635, osteoarthritis/arthrosis/OA, 
cartilage/chondrocytes, synovium/synovial/synovio  cytes, 
and bone. Celecoxib studies regarding its eﬀ  ects  on 
cartilage, bone, and synovium were selected by screening 
title and abstract. Publications not written in English or 
not containing original data were excluded. Reviews 
concerning subjects like the cost-eﬀ  ectiveness  and 
cardiovascular/gastrointestinal side eﬀ   ects of celecoxib 
and the use of celecoxib in cancer treatment have been 
published and are therefore not covered in this review.
Celecoxib: direct eff  ects on cartilage
In OA, chondrocytes fail to maintain the equilibrium 
between synthesis and degradation of the extracellular 
matrix, resulting in progressive disruption of the struc-
tural integrity of cartilage. Initially, chondrocytes com-
pen  sate for the enhanced catabolic processes by increas-
ing synthesis of collagens and proteoglycans. However, as 
OA progresses, the increasing catabolic enzyme activity 
can no longer be counterbalanced [14]. IL-1β and TNF-α 
play key roles in the destructive process by stimulating 
expression and release of proteases, such as collagenases 
and aggrecanases, including matrix metalloproteinases 
(MMPs) and a disintegrin and metalloproteinase with 
trombospondin repeats (ADAMTS), which degrade 
collagen and aggrecan. Th  ese pro-inﬂ  ammatory  cyto-
kines stimulate synthesis and release of nitric oxide (NO) 
and PGE2 [15]. Chondrocytes from OA patients show 
elevated COX-2 expression, and its product PGE2 is 
increased in OA cartilage [16]. Th   e function of PGE2 in 
OA is not exactly clear as it has both catabolic and 
anabolic eﬀ   ects in cartilage [17,18]. NSAIDs could 
potentially aﬀ   ect cartilage through their inhibition of 
PGE2 production.
Proteoglycan turnover
Celecoxib dose-dependently inhibits glycosaminoglycan 
release and stimulates proteoglycan synthesis in healthy 
human articular cartilage explants when exposed to 
peripheral blood mononuclear cells from rheumatoid 
arthritis patients or IL-1β and TNF-α [19]. Th   e fact that 
the decreased proteoglycan synthesis induced by IL-1β 
and TNF-α is reversed by celecoxib indicates that this 
drug can also exert its eﬀ  ects directly on activated carti-
lage. Furthermore, in OA cartilage explants, celecoxib 
stimulated proteoglycan synthesis and retention of newly 
formed proteoglycans [20-22]. Th  e non-selective COX 
inhibitors diclofenac and naproxen did not aﬀ  ect proteo-
glycan turnover in OA cartilage, and indomethacin and 
an experimental COX-1 selective inhibitor (SC-560) had 
adverse eﬀ  ects [20,21]. Th  is  diﬀ  erence in NSAID eﬀ  ects 
supports COX-2 involvement in catabolic activity regula-
tion in cartilage, whereas COX-1 activity might have a 
more physiological role in chondrocytes.
No eﬀ  ect of celecoxib on proteoglycan turnover was 
observed in healthy cartilage [19,22]. Th   is is in contrast 
to the protective in vitro eﬀ  ect of celecoxib on end-stage 
OA cartilage obtained at joint replacement surgery. For 
the treatment of OA in clinical practice, it would be 
beneﬁ   cial if celecoxib could inﬂ  uence  proteoglycan 
turnover in earlier stages of disease. It was shown that in 
both degenerated (pre-clinical) and late-stage OA carti-
lage, celecoxib not only stimulated proteoglycan synthesis 
and retention of newly formed proteoglycans, but also 
had favorable eﬀ  ects on proteoglycan content. Impor-
tantly, proteoglycan content in degenerated cartilage nor-
ma l ized in vitro during celecoxib treatment, suggesting 
celecoxib treatment in the early stages of OA could slow 
down or even reverse the destructive process [22].
Whereas the in vitro eﬀ   ects of celecoxib on OA 
cartilage are beneﬁ   cial, results obtained with isolated 
chondrocytes are not consistent. In a mechanically 
stretched monolayer of chondrocytes, celecoxib had a 
positive eﬀ  ect on aggrecan expression and reduced the 
release of chondroitin sulfate [23]. In contrast, celecoxib 
had no positive eﬀ  ect on proteoglycan turnover of osteo-
arthritic chondrocytes cultured in alginate beads [24], of 
a monolayer of chondrocytes [25], nor in an in vitro 
model of post-traumatic OA [26]. Th  is variation in the 
eﬀ  ects of celecoxib could potentially be due to diﬀ  erences 
in chondrocyte culture models, whereas cartilage 
explants probably better reﬂ  ect the in vivo situation.
Prostaglandin E2-induced catabolism
A possible way in which celecoxib exerts its eﬀ  ect on 
proteo  glycan turnover is inhibition of PGE2 production. 
PGE2 is highly expressed in OA cartilage and studies 
indicate a pivotal role for PGE2 in OA cartilage meta-
bolism [27]. Expression of PGE2 and COX-2 in OA 
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28,29]. PGE2 enhances IL-1β-/TNF-α-induced proteo  gly-
can release, resulting in decreased proteoglycan content 
in cartilage explants [28]. Th  e eﬀ   ect of PGE2 on the 
synthesis of proteoglycans remains controversial; in OA 
cartilage, proteoglycan synthesis is inhibited by PGE2 
[17], whereas PGE2 does not aﬀ  ect proteoglycan synthesis 
rate in healthy cartilage [28]. Th   is discrepancy could be 
due to diﬀ   erences in expression levels of individual 
members of the EP receptor family (EP1 to EP4) through 
which PGE2 exerts its eﬀ  ects. EP4 has been implicated in 
mediating catabolic eﬀ  ects because it is highly expressed 
in OA cartilage [17]. IL-1-induced expression of EP4 in 
cultured OA chondrocytes is decreased by celecoxib [29], 
but not consistently [17]. Th  e overall negative eﬀ  ect of 
PGE2 on proteoglycan turnover in cartilage might be 
mediated through the EP4 receptor (Figure 1).
PGE2 inhibits collagen synthesis and stimulates expres-
sion of MMP and ADAMTS-5, proteolytic enzymes in-
volved in the degradation of collagens and proteo  glycans 
[17,30,31]. Th  eoretically, celecoxib could also prevent 
cartilage destruction by inhibiting induction of MMP 
expression in OA cartilage. Both inhibitory and stimu-
latory eﬀ  ects of celecoxib on IL-1-induced expres  sion of 
MMP-13 in OA chondrocytes have been reported 
[10,17]. Also, there is no agreement on the eﬀ  ect  of 
Figure 1. Schematic representation of the in vitro eff  ects of celecoxib (CBX) on cartilage degeneration. Cyclooxygenase (COX)-2 expression 
in the chondrocyte is induced by infl  ammatory mediators such as IL-1β and TNF-α (1). Subsequently, the prostanoid receptor EP4 is up-regulated 
via a COX-2-dependent mechanism (2). Increased COX-2 activity results in large concentrations of prostaglandin E2 (PGE2) (3). PGE2 exerts its 
eff  ects through the prostanoid receptor EP4 (4), resulting in the increased expression of matrix metalloproteinases (MMPs) and a disintegrin and 
metalloproteinase with thrombospondin repeats (ADAMTS)-5. Furthermore, PGE2 augments the release of newly formed proteoglycans from 
cartilage and reduces the synthesis of proteoglycans (5). IL-1β and TNF-α also activate the transcription factors NF-κB and JNK (6), which stimulate 
the expression of inducible nitric oxide synthase (iNOS) (7), resulting in the formation of nitric oxide (NO) (8). NO has a potential role in inducing 
chondrocyte apoptosis, inhibiting proteoglycan synthesis and stimulating MMP activity (9). Together, the eff  ects of NO and PGE2 result in cartilage 
degeneration. Celecoxib prevents the negative eff  ects of PGE2 and NO on cartilage destruction by inhibiting both COX-2 and NF-κB/JNK, thereby 
potentially slowing cartilage degradation in osteoarthritis.
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Celecoxib reverses IL-1β-induced ADAMTS-5 expres  sion 
in OA cartilage explants [17]. As such, it could prevent 
enhanced proteoglycan turnover in OA by aﬀ  ecting both 
MMP and ADAMTS-5 expression. But our understand-
ing of the inﬂ   uence of celecoxib on PGE2-induced 
cartilage catabolism is clearly far from complete and it 
would be worthwhile to explore this role in more detail.
Nitric oxide, NF-κB, and chondrocyte apoptosis
NO plays an important role in cartilage destruction in 
OA - for example, by inhibiting matrix synthesis, activat-
ing MMPs, and inducing chondrocyte apoptosis [33-35]. 
Because NO is an attractive target in OA treatment, 
several studies have addressed the question of whether 
celecoxib inﬂ   uences NO production, although little 
agree  ment has been reached. Several studies found 
inhibi tory  eﬀ   ects of celecoxib on NO production in 
chondro  cytes [25,32,36], whereas others did not [28,37]. 
Th   ese contradictory eﬀ  ects are potentially due to diﬀ  er-
ences in culture models, treatment duration, and 
celecoxib concentration used.
In articular chondrocytes, NO production is regulated 
by NF-κB, JunNH2-terminal kinase (JNK) and p38 
[32,38]. Celecoxib was shown to suppress NO production 
by inactivating JNK and NF-κB [32]. An inhibitory eﬀ  ect 
of celecoxib on NF-κB signaling in OA chondrocytes was 
reported previously [10]. NF-κB has an essential role in 
OA pathogenesis, being involved in cytokine stimulation, 
MMP and ADAMTS expression, and diminished secre-
tion of extracellular matrix proteins by chondrocytes.   
Inhibition of NF-κB could potentially be beneﬁ  cial in OA 
treatment. Interestingly, it was reported that celecoxib 
reduces expression of IL-1 [37] and IL-6 [24], both 
inﬂ   am  matory cytokines involved in OA pathogenesis 
[39]. It is currently unknown how celecoxib mediates its 
eﬀ  ects on cytokine expression and NF-κB activity.
Celecoxib induced apoptosis in a dose-dependent 
manner in chondrocytes derived from cartilage from 
patients with OA [25], although reduced apoptosis via 
COX inhibition by celecoxib has also been reported [26].
In general, celecoxib has favorable eﬀ  ects on cartilage 
destruction in vitro, thereby theoretically slowing down 
disease progress in vivo (Figure 1).
Celecoxib: eff  ects on synoviocytes
Inhibition of signal transduction and pro-infl  ammatory 
mediators
Although originally viewed as a non-inﬂ  ammatory 
arthro  pathy, a pivotal role of synovial inﬂ  ammation in 
OA progression is now recognized. Imaging studies have 
shown synovium changes in early and late OA [40]. 
Histologically, synovium from OA patients shows hyper-
plasia, increased lining layer thickness, blood vessel 
for  ma  tion and mononuclear cell inﬁ  ltration,  mainly 
consist  ing of macrophage like cells. IL-1β and TNF-α 
levels are increased in OA synoviocytes, potentially 
contributing to disease progression by activating 
chondrocytes and synovial ﬁ  broblasts [41,42]. Enhanced 
PGE2 and COX-2 expression in synovial ﬂ  uid  and 
synovial membrane have been observed [43,44]. Several 
eﬀ   ects of celecoxib on synovium, with a focus on 
ﬁ  broblasts, have been des  cribed. Celecoxib reversed IL-1β-
induced PGE2 and COX-2 protein expression in synovial 
ﬁ   broblasts. Further  more, celecoxib inhibited IL-1β-
induced activa  tion of NF-κB in synovial ﬁ  broblasts from 
OA patients [10]. NF-κB induces expression of large 
numbers of inﬂ  ammatory mediators and plays a major 
role in the initiation and maintenance of synovitis, 
synovial hyperplasia, and inhibition of synovial apoptosis 
in rheumatoid arthritis. Although less is known 
concerning the function of NF-κB in osteoarthritic 
synovium, it is clear that celecoxib could reduce 
expression of various inﬂ  amma  tory mediators by down-
regulation of NF-κB [45].
Proteolysis
Among the downstream factors of NF-κB are MMPs, 
which play a crucial role in cartilage degradation in OA. 
Both MMP-1 and MMP-13 levels are enhanced in OA; 
MMP-1 is predominantly released by synovial cells, and 
MMP-13 is highly expressed by chondrocytes [46]. 
MMP-2 and MMP-9 are also elevated in the osteo-
arthritic joint. MMP-2 expression is regulated by COX-2. 
Several NSAIDs, including celecoxib, inhibit MMP-2 
secretion in OA synovial ﬁ  broblast cultures [47]. Further-
more, celecoxib can decrease the expression of MMP-9 
and urokinase-type plasminogen activator (u-PA) and its 
inhibitor PAI [47]. Alterations in u-PA and PAI expres-
sion have been found in osteoarthritic tissue and contri-
bute to a disturbed proteolytic balance [48].
It was shown that celecoxib, but no other selective 
COX-2 inhibitors, enhances MMP-1 and MMP-13 protein 
expression in IL-1β-stimulated synoviocytes [10,49]. Th  is 
observation does not corroborate the inhibitory eﬀ  ect of 
celecoxib on MMP-1 expression in rheumatoid arthritis 
synoviocytes [50]. Th  is discrepancy could be due to 
diﬀ  erent concentrations used, celecoxib being stimula-
tory at low concentrations (0.5 to 1 μM) and inhibitory at 
higher concentrations (5 to 10 μM). Evidently, a stimula-
tory eﬀ  ect of celecoxib on synovial MMP-1 and MMP-13 
expression could be detrimental in OA treatment [10]. In 
conclusion, celecoxib inﬂ  uences the balance of proteo-
lytic enzymes in OA synovium, and although this appears 
to be generally beneﬁ   cial (reducing expression of 
MMP-2, MMP-9, and uPA), adverse eﬀ  ects have been 
reported as well (increas  ing expression of MMP-1 and 
MMP-13).
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Recently, it was shown that celecoxib dose-dependently 
inhibits proliferation and induces apoptosis in synovial 
ﬁ  broblasts obtained from OA patients [51,52]. Th   is is in 
agreement with ﬁ  ndings in rheumatoid arthritis [53-55]. 
Remarkably, various other COX-2 selective inhibitors, 
including nimesulide and rofecoxib, did not induce 
apoptosis of synovial ﬁ  broblasts, indicating that celecoxib 
stimulates apoptosis in a COX-2-independent manner 
[51]. In cancer cells celecoxib has been shown to modu-
late apoptosis pathways by inhibiting anti-apoptotic 
proteins, elevating Ca2+ concentration and altering NF-kB 
signaling (reviewed in [56]). Although the exact pro-
apoptotic mechanism of celecoxib in synovial tissue 
remains to be established, it is evident that anti-
proliferative and pro-apoptotic eﬀ   ects of celecoxib on 
synovium are beneﬁ  cial in reducing synovial hyperplasia 
and potentially slow down synovitis-mediated OA 
disease progress.
Taken together, celecoxib modulates several pathogenic 
mechanisms of synovial cells that are not always aﬀ  ected 
by other NSAIDs, suggesting that celecoxib may have 
additional, COX-2-independent value in the treatment of 
OA (Figure 2).
Celecoxib: eff  ects on subchondral bone
Subchondral bone in osteoarthritis
Subchondral bone sclerosis and osteophyte formation are 
radiographic hallmarks of end-stage OA. Several studies 
suggest that bone remodeling in OA is biphasic: an early 
decrease in trabecular bone formation, followed by an 
increase in subchondral bone density and stiﬀ  ness 
[57,58]. Th  e initial thinning of the subchondral plate 
coincides with changes in articular cartilage, suggesting a 
pivotal role for the cartilage and subchondral bone inter-
action in OA progression. In established OA, the 
increased subchondral bone stiﬀ   ness probably contri-
butes to further cartilage degeneration [59].
Osteoclastogenesis
Osteoclasts play a pivotal role in the destruction of 
subchondral bone [4,14,59]. Osteoclastogenesis and acti-
va  tion of mature osteoclasts are critically regulated by 
the receptor activator of NF-κB ligand (RANKL). RANKL 
mediates its function by binding to its cell-surface 
receptor RANK on osteoclast precursor cells and osteo-
clasts, thus stimulating diﬀ  erentiation and activation of 
osteoclasts. It is mainly expressed by osteoblasts and 
stromal cells, where expression of RANKL is 
Figure 2. Schematic representation of the major actions of celecoxib (CBX) in synovium. In osteoarthritic synovium, increased levels of 
IL-1β and TNF-α stimulate the expression of cyclooxygenase (COX)-2 and the ensuing production of prostaglandin E2 (PGE2). PGE2 augments 
the expression of proteolytic enzymes, including matrix metalloproteinases (MMPs) and urokinase-type plasminogen activator (uPA), thereby 
contributing to the destruction of the articular joint. Celecoxib has a benefi  cial eff  ect on synovium through its inhibition of COX-2 (1). In addition, 
celecoxib inhibits IL-1β-induced activation of NF-κB, and hence diminishes the expression of various infl  ammatory mediators (2). A third potential 
favorable eff  ect of celecoxib on synovium is its induction of apoptosis in synovial fi  broblasts (3). This would theoretically contribute to decreased 
synovial hyperplasia and reduced expression of infl  ammatory mediators. PAI, plasminogen activator inhibitor.
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also produced by T lymphocytes and ﬁ  broblast-like 
synovio  cytes. Osteoprotegerin (OPG), a soluble decoy 
receptor for RANKL, can prevent the biological eﬀ  ects of 
RANKL, and the ratio between OPG and RANKL 
determines whether the balance is in favor of bone 
resorption or bone formation [61,62]. Interestingly, two 
osteoblast sub  populations were identiﬁ   ed in OA, one 
with a low OPG/RANKL ratio that favors bone 
resorption, and one with a high OPG/RANKL ratio that 
promotes bone formation [61,63]. Inhibition of COX-2 
by NSAIDs diminishes RANKL production by 
osteoblasts, and since RANKL is an important inducer of 
osteoclastogenesis, celecoxib inhibited osteoclast 
diﬀ   erentiation in co-cultures of osteo  blasts and bone 
marrow-derived cells [12,64]. Besides aﬀ  ecting 
osteoclastogenesis indirectly through its eﬀ  ect  on 
osteoblasts, celecoxib also directly inﬂ  uenced osteo  clast 
precursor cells by inhibiting COX-2 expression. Adding 
celecoxib to bone marrow-derived monocyte/
macrophage cells, in the absence of stromal cells, 
suppresses RANKL-induced osteoclast diﬀ  erentiation 
[65,66]. Th  is celecoxib eﬀ   ect was reversed by PGE2, 
indicat  ing that RANKL-induced COX-2 and PGE2 
expression in osteoclast precursors is critically involved 
in osteoclastogenesis [65] (Figure 3).
Osteoclast activity
Besides inhibiting osteoclast diﬀ  erentiation, celecoxib is 
able to almost completely inhibit the activity of human 
osteoclasts [66]. Slightly lesser eﬀ  ects were observed with 
indomethacin, and no eﬀ  ects were seen with a selective 
COX-1 inhibitor, suggesting a COX-2-dependent path-
way is involved [66]. However, other mechanisms might 
be involved in inhibiting osteoclast activity as well. 
Celecoxib, as well as other sulfonamide-type COX-2 inhi-
bi  tors, contain an aryl sulfonamide moiety that inhibits 
carbonic anhydrase II [67]. Abundantly expressed on the 
inner surface of osteoclasts, carbonic anhydrase II 
catalyzes conversion of CO2 and H2O into bicarbonate 
and H+. Acidiﬁ  cation in the resorption pit is required for 
dissolution of the inorganic matrix of bone [68]. 
Treatment with celecoxib reduced carbonic anhydrase 
activity and thereby inhibited osteoclast activity, an eﬀ  ect 
not observed for COX-inhibitors without this sulfona-
mide moiety [12].
Osteoprotegerin/RANKL in chondrocytes
Recently, it was found that human chondrocytes express 
OPG, RANKL and RANK [61,69]. Interestingly, the 
OPG/RANKL ratio is signiﬁ  cantly lower in OA chondro-
cytes compared to healthy chondrocytes [70]. Th  is  shift 
in OPG/RANKL ratio is mediated by PGE2 [69,71], and 
inhibition of PGE2 production by celecoxib resulted in a 
higher OPG/RANKL ratio [71,72]. It was shown that 
RANKL produced by chondrocytes can stimulate osteo-
clasto  genesis [73,74] and, furthermore, as a chemo-
attractant for peripheral blood monocytes, it could 
attract osteoclast precursor cells to the joint [75]. Inhibi-
tion of chondrocyte RANKL expression by celecoxib 
might thus prevent subchondral bone loss (Figure 3).
Celecoxib: eff  ects in vivo
Cartilage
In vitro experiments have shown a cartilage-sparing 
eﬀ  ect of celecoxib in OA cartilage; however, in vivo data, 
from either human or animals, are scarce. Contrary to its 
positive eﬀ   ects on cartilage degeneration in vitro, no 
chondroprotective eﬀ   ect of celecoxib in the canine 
groove model of OA was observed [76]. Although PGE2 
levels in the joint were inhibited, celecoxib did not 
improve cartilage histopathology or proteoglycan turn-
over. Th  is lack of chondroprotective eﬀ  ect might have 
been due to increased loading of the joint in the 
celecoxib-treated group compared to the placebo-treated 
group, where no analgesics were given [76]. Conversely, 
celecoxib was shown to reduce cartilage damage in 
collagen-induced osteoarthritis in rabbits; histopatho-
logical evaluation showed less cartilage erosion, reduced 
cartilage ﬁ  brillation and decreased loss of chondrocytes. 
Proteoglycan content, determined by Safranin-O staining 
intensity, was higher than in the placebo-treated group 
[77]. Next to the direct eﬀ  ects of celecoxib, the anti-in-
ﬂ  ammatory  eﬀ   ects of celecoxib may have caused this 
chondroprotective eﬀ   ect as the model depends on 
inﬂ  ammation and the number of inﬂ  ammatory cells and 
the PGE2 concentration in synovial ﬂ  uid was signiﬁ  cantly 
reduced by celecoxib.
Few studies have described the in vivo eﬀ  ects  of 
celecoxib on cartilage destruction in OA patients [37, 
44,78-80]. However, these studies generally have limita-
tions with respect to their small size and short duration. 
A way to study drug eﬀ  ects is to treat patients with severe 
knee OA waiting for joint replacement surgery and 
analyze the cartilage ex vivo. In this manner, a beneﬁ  cial 
eﬀ  ect of celecoxib on cartilage degradation after 4 weeks 
of treatment was observed [78]. Although no diﬀ  erences 
in the histopathological Mankin score were observed, 
proteoglycan synthesis rate and retention of newly 
formed proteoglycans was signiﬁ   cantly increased in 
celecoxib-treated OA patients compared to indomethacin-
treated or untreated patients. Th  e expression of key 
players in the destructive process, NO and PGE2, was 
inhibited by both celecoxib and indomethacin [78]. 
Hence, diﬀ   erences in cartilage proteoglycan turnover 
between celecoxib- and indomethacin-treated patients 
could result from speciﬁ  c  eﬀ   ects of indomethacin-
induced COX-1 inhibition on cartilage [20,21], or from 
Zweers et al. Arthritis Research & Therapy 2011, 13:239 
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similar approach, long-term (3 months) eﬀ  ects  of 
celecoxib and aceclofenac were studied in OA patients 
[37]. It was demonstrated that expression of COX-2, 
microsomal prostaglandin E synthase-1 (mPGES-1) and 
inducible NO synthase, an enzyme involved in NO 
generation, was strongly reduced in both celecoxib- and 
aceclofenac-treated patients. Only celecoxib was shown 
to inhibit expression of the PGE2 receptors EP2 and EP4, 
as well as TNF-α and IL-1β, in articular cartilage. A 
positive correlation exists between TNF-α/IL-1β levels 
and cartilage damage [81], suggesting a chondro-
protective eﬀ  ect of celecoxib in vivo.
Th  e  eﬀ  ects of celecoxib treatment on disease progres-
sion are more ambiguous [79,80,82]. In an observational 
study, conventional NSAID use was associated with 
enhanced cartilage destruction compared to selective 
COX-2 inhibitors. Furthermore, the COX-2 inhibitors 
rofecoxib and celecoxib showed beneﬁ  cial  eﬀ  ects  on 
tibial cartilage defects in knee OA compared to no 
medication [82]. Recently, the eﬀ  ect of celecoxib treat-
ment (200 mg daily, 12 months) on cartilage volume loss 
was studied compared to a historical cohort of patients 
receiving standard care [79]. Using quantitative magnetic 
resonance imaging, no protective celecoxib eﬀ  ect  on 
knee cartilage was found. Only one randomized 
controlled trial has addressed the eﬀ  ects of celecoxib on 
cartilage degeneration [80]. Patients who met radio-
graphic criteria grade 2 and 3 (Kellgren and Lawrence) 
were blinded and given celecoxib, chondroitin sulfate, 
glucosamine or placebo. Unexpectedly, no diﬀ  erences in 
joint space narrowing (measured radiographically) or 
Figure 3. Schematic representation of the main eff  ects of celecoxib (CBX) on subchondral bone. IL-1β induces the expression of 
cyclooxygenase (COX)-2 in chondrocytes (1) and osteoblasts (2), leading to production of receptor activator of NF-κB ligand (RANKL). RANKL 
stimulates the diff  erentiation of osteoclast precursor cells into quiescent osteoclasts (3). Furthermore, it induces the expression of COX-2 and 
prostaglandin E2 (PGE2) in quiescent osteoclasts, and subsequently PGE2 activates osteoclasts in both an autocrine and paracrine manner (4). 
Celecoxib inhibits the COX-2-dependent RANKL production by chondrocytes and osteoblasts, thereby avoiding osteoclastogenesis and osteoblast 
activity. Furthermore, celecoxib directly inhibits the diff  erentiation of precursor cells, independent of RANKL production by stromal cells. Celecoxib 
can also directly aff  ect the osteoclasts themselves by decreasing RANKL-induced PGE2 expression and inhibiting carbonic anhydrase. Decreased 
carbonic anhydrase activity will diminish acidifi  cation of the resorption pit, and hence decrease osteoclast activity (5).
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treated groups were observed after 2 years follow-up 
[80]. Less than anticipated loss of joint space width in the 
placebo-treated group hampered the study and prevented 
a strong conclusion. Moreover, the results found in these 
studies were obtained in an un-controlled trial set-up 
and, as such, could be aﬀ   ected by the selection of 
patients. Also, the numbers of patients used in most 
studies is rather limited.
Figure 4 summarizes the suggested in vivo eﬀ  ects of 
celecoxib. Th  e beneﬁ  cial in vitro eﬀ  ects and the some-
what controversial in vivo eﬀ   ects on cartilage, mostly 
based upon weak evidence, clearly indicate the require-
ment for properly designed randomized controlled trials 
on the potential disease-modifying osteoarthritic drug 
eﬀ  ects of celecoxib.
Synovium
Celecoxib has been shown to reduce synovitis, leukocyte 
inﬁ  ltration and synovial hyperplasia in diﬀ  erent arthritis 
animal models [83-85]. In the synovium of severe knee 
OA patients, inhibitory eﬀ  ects of celecoxib on IL-1β and 
TNF-α expression have been demonstrated [44,78]. 
Further  more, celecoxib reduced IL-6 concentrations in 
the synovial ﬂ  uid of patients with moderately severe OA 
after 2 weeks of treatment [86]. Interestingly, aceclofenac 
and indomethacin had no or only moderate eﬀ  ects on 
cytokine expression in these studies [44,78].
Reduction of pro-inﬂ  ammatory cytokines in synovial 
ﬂ   uid by celecoxib could be the result of decreased 
production by chondrocytes, as has been shown in vitro 
[24]. However, synovial macrophages are also an impor-
tant source of pro-inﬂ  ammatory cytokines [42]. Ex vivo 
analysis of OA synovium after in vivo celecoxib treatment 
showed a signiﬁ  cant reduction in synovial macrophage 
numbers, which was not observed for aceclofenac [44]. 
Th  is macrophage depletion might be due to enhanced 
apoptosis in response to celecoxib, which has a pro-
apoptotic eﬀ  ect on synoviocytes and macrophages [51, 
53,55]. Decreasing macrophage numbers would result in 
lower pro-inﬂ  ammatory mediator levels in synovial ﬂ  uid. 
Only one study has addressed the inﬂ  uence of celecoxib 
on MMP activity in synovial tissue; despite controversial 
results on MMP activity in synoviocytes in vitro, no 
celecoxib eﬀ  ect on MMP activity was demonstrated in 
vivo [78].
In conclusion, under certain conditions pro-inﬂ  am-
matory cytokines play a crucial role in OA pathogenesis 
by inhibiting proteoglycan synthesis, inducing chondro-
cyte apoptosis and activating other cells. Preventing 
enhanced production of these inﬂ  ammatory mediators 
by celecoxib will likely slow disease processes. Several 
lines of evidence indicate that synovial changes can be 
among the ﬁ   rst to occur in OA (reviewed in [87]), 
suggesting early treatment could slow or maybe prevent 
joint damage. As little research has focused on the eﬀ  ects 
of celecoxib on synovial tissue, further research should 
elucidate the eﬀ  ects of celecoxib in disease progression.
Bone
Various studies have shown a beneﬁ  cial  eﬀ  ect  of 
celecoxib on bone in vivo [12,88-90]. Celecoxib, but not 
other NSAIDs, reduced bone mineral density loss 
[12,88,90] and enhanced trabecular bone volume in 
adjuvant- and collagen-induced arthritis in rats [88-90]. 
Th  e increased trabecular bone volume correlated with 
reduced serum type I collagen C-telopeptide, a bone 
resorption marker representing osteoclast activity [12,88], 
and other bone resorption parameters [89]. Whereas 
celecoxib did not aﬀ  ect bone formation, it suppressed 
osteoclast numbers in tibia of arthritic animals [89,90]. 
Th   ese celecoxib eﬀ  ects were partly mediated by RANKL, 
as celecoxib decreased expression of RANKL in synovial 
tissue, bone marrow cells and cartilage in vivo [71,89]. As 
shown  in vitro, celecoxib inhibited both osteoclasto-
genesis and osteoclast activation, thereby directly 
diminishing bone destruction.
Figure 4. Summary of the eff  ects of celecoxib on osteoarthritis 
in vivo (animal and human). Celecoxib has diff  erent in vivo eff  ects 
in the diff  erent tissues of the osteoarthritic knee joint. In cartilage 
celecoxib has a positive eff  ect on proteoglycan content, as well as an 
inhibiting eff  ect on several mediators of infl  ammatory and cartilage 
destruction processes. In synovial tissue celecoxib shows inhibiting 
eff  ects on cytokines and the number of synovial macrophages. 
Celecoxib shows a positive eff  ect on trabecular bone volume and a 
negative eff  ect on bone resorption and the number of osteoclasts 
in subchondral bone. COX, cyclooxygenase; iNOS, inducible nitric 
oxide synthase; MMP, matrix metalloproteinase; NO, nitric oxide; PGE2, 
prostaglandin E2.
Cartilage
Ĺ proteoglycan content
Ļ iNOS, NO
Ļ COX-2, PGE2, EP2, EP4
Ļ MMP-1, MMP-13
Ļ IL-1ȕ, TNFĮ
Synovium
Ļ IL-1ȕ,IL-6,TNFĮ
Ļ number of synovial 
macrophages
Subchondral bone
Ĺ trabecular bone volume
Ļ bone resorption
Ļ number of osteoclasts
Zweers et al. Arthritis Research & Therapy 2011, 13:239 
http://arthritis-research.com/content/13/5/239
Page 8 of 11Despite celecoxib being used for treatment of OA for 
many years, no eﬀ  ects of it on serum markers of bone 
resorption and formation or on structural changes in 
bone have been reported. As celecoxib has beneﬁ  cial 
eﬀ  ects on bone resorption in vitro and in vivo in animal 
models, it would be interesting to explore these eﬀ  ects on 
bone metabolism in OA patients in more detail.
Conclusion
Despite celecoxib being approved for OA treatment for 
over a decade, few studies have addressed the disease-
modifying properties of this selective COX-2 inhibitor, 
speciﬁ  cally  in vivo. Th  is review does not address the 
clinical risk and side eﬀ  ects related to the clinical beneﬁ  ts 
of celecoxib but focuses on the disease-modifying 
properties of this compound. However, the increased risk 
of myocardial infarction and worsening of high blood 
pressure can not be ignored when prescribing celecoxib. 
Th  ese issues have been extensively described in other 
reviews and are still under discussion at present. Also, it 
is not the intention of this review to compare in a 
systematic way the disease-modifying eﬀ  ects of celecoxib 
with other coxibs and conventional NSAIDs. As such, all 
eﬀ  ects described might be partly class-speciﬁ  c and partly 
celecoxib-speciﬁ  c. Nonetheless, celecoxib’s chondro  pro-
tec tive  eﬀ  ects - prevention of synovial hyperplasia, and 
inhibition of bone destruction in vitro and in vivo 
speciﬁ  cally in animal models - suggest that it and maybe 
other coxibs could potentially slow OA disease progres-
sion in humans. At present, however, good quality 
randomized controlled trials examining the disease-
modifying eﬀ  ects of celecoxib are lacking. Future studies 
should elucidate the actual role of celecoxib and other 
selective coxibs as disease-modifying osteoarthritic 
drugs.
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